FIB-4 Test Limitations in MASLD Diagnosis

The FIB-4 (Fibrosis-4) index, a commonly used blood test to assess liver fibrosis, may not be reliable for accurately identifying fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). A recent study highlights limitations in its performance, particularly in primary care settings.

Understanding MASLD and the Importance of Fibrosis Detection

MASLD is a prevalent chronic liver disease affecting an estimated 32.4% of the global population. [1] It develops when excessive fat accumulates in the liver (steatosis) alongside cardiometabolic risk factors like dyslipidemia, hypertension, or type 2 diabetes. The disease can progress from simple steatosis to more severe conditions, including inflammation (MASH), fibrosis, cirrhosis, and even hepatocellular carcinoma. Detecting fibrosis, especially stage F2 or higher, is crucial because it’s linked to poorer liver and overall health outcomes. [1]

The FIB-4 Index: A Convenient but Imperfect Tool

The FIB-4 index is calculated using readily available blood test results: age, levels of the liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT), and platelet count. [2] Its accessibility and low cost make it a popular initial screening tool. However, its accuracy can vary, especially in patient groups at higher risk for MASLD, such as those with obesity, type 2 diabetes, or cardiovascular disease.

Study Findings: Limited Agreement with VCTE

Researchers evaluated the FIB-4 index in a prospective cohort study involving 1,285 participants across nine Belgian and five Dutch primary care practices (October 2020 – February 2024). [2] Liver stiffness, used as a surrogate marker for fibrosis, was estimated using vibration-controlled transient elastography (VCTE). The study revealed only slight agreement between fibrosis classifications based on the FIB-4 index and those determined by VCTE, regardless of demographic characteristics or clinical risk factors. [2]

High Rates of False Positives and False Negatives

Using current FIB-4 thresholds, the study found significant rates of both false positive and false negative results. For individuals 65 years and younger, over 81.6% of referrals triggered by a FIB-4 index of 1.3 or higher were not confirmed by VCTE. [2] In those older than 65, the over-referral rate was 73.7%. The index also missed some cases of fibrosis, with false negative rates of 8.8% in younger participants and 18.5% in those over 65. [2] Performance was particularly limited in individuals with type 2 diabetes and obesity.

Exploring Alternative Cut-offs

Researchers explored alternative age-based cut-offs (1.29 for those ≤65 years and 1.72 for those >65 years) and validated them in cohorts from Türkiye and a Belgian secondary care setting with type 2 diabetes. [2] While the 1.29 cut-off performed similarly to the existing 1.3, the 1.72 cut-off showed improved sensitivity but lower specificity.

Implications for MASLD Screening

While the FIB-4 index can be useful for population-level screening, its reliability for individual risk assessment is limited. MASLD is often asymptomatic until advanced fibrosis develops, making early detection critical. Non-invasive tools like FIB-4 and VCTE are valuable for risk stratification in primary care, but an unreliable tool can lead to unnecessary referrals, missed diagnoses, and inappropriate management. [2]

Impact on Quality of Life

Recent research indicates that MASLD, even in cases with low fibrosis prevalence, is associated with decreased general health perception, reduced quality of life, and impaired work productivity. [3] This underscores the importance of accurate diagnosis and management of the condition.